Marcos Bonilla-Hernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marcos Bonilla-Hernández has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Sánchez-Recillas
Laboratorio de Farmacología, Facultad de Química, Universidad Autónoma de Yucatán, Merida 97069, Yucatan, Mexico
2 shared publications - Rolffy Ortiz-Andrade
Facultad de Química, Universidad Autónoma de Yucatán (UADY), Mérida 97069, Yucatán, Mexico
2 shared publications - Sergio Hidalgo-Figueroa
CONAHCyT-División de Biología Molecular, Instituto Potosino de Investigación Científica y Tecnológica A.C, San Luis Potosí, San Luis Potosí, 78216, México
2 shared publications - Angel Josabad Alonso-Castro
División de Ciencias Naturales and Exactas, Universidad de Guanajuato, Guanajuato, Mexico
1 shared publication - Angélica Meneses-Acosta
Universidad Autónoma del Estado de Morelos
1 shared publication - Carlos Alberto Tavira-Montalvan
Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, Cuernavaca 62209, México
1 shared publication
Latest Publications
- Open Access
Melanin Nanoparticles Obtained from Preformed Recombinant Melanin by Bottom-Up and Top-Down Approaches
Melanin is an insoluble, amorphous polymer that forms planar sheets that aggregate naturally to create colloidal particles with several biological functions. Based on this, here, a preformed recombinant melanin (PRM) was utilized as the polymeric raw material to generate recombinant melanin nanoparticles (RMNPs). These nanoparticles were prepared using bottom-up (nanocrystallization—NC, and double emulsion–solvent evaporation—DE) and top-down (high-pressure homogenization—HP) manufacturing approaches. The particle size, Z-potential, identity, stability, morphology, and solid-state properties were evaluated. RMNP biocompatibility was determined in human embryogenic kidney (HEK293) and human epidermal keratinocyte (HEKn) cell lines. RMNPs prepared by NC reached a particle size of 245.9 ± 31.5 nm and a Z-potential of −20.2 ± 1.56 mV; 253.1 ± 30.6 nm and −39.2 ± 0.56 mV compared to that obtained by DE, as well as RMNPs of 302.2 ± 69.9 nm and −38.6 ± 2.25 mV using HP. Spherical and solid nanostructures in the bottom-up approaches were observed; however, they were an irregular shape with a wide size distribution when the HP method was applied. Infrared (IR) spectra showed no changes in the chemical structure of the melanin after the manufacturing process but did exhibit an amorphous crystal rearrangement according to calorimetric and PXRD analysis. All RMNPs presented long stability in an aqueous suspension and resistance to being sterilized by wet steam and ultraviolet (UV) radiation. Finally, cytotoxicity assays showed that RMNPs are safe up to 100 μg/mL. These findings open new possibilities for obtaining melanin nanoparticles with potential applications in drug delivery, tissue engineering, diagnosis, and sun protection, among others.
Open AccessMelanin Nanoparticles Obtained from Preformed Recombinant Melanin by Bottom-Up and Top-Down Approaches
Melanin is an insoluble, amorphous polymer that forms planar sheets that aggregate naturally to create colloidal particles with several biological functions. Based on this, here, a preformed recombinant melanin (PRM) was utilized as the polymeric raw material to generate recombinant melanin nanoparticles (RMNPs). These nanoparticles were prepared using bottom-up (nanocrystallization—NC, and double emulsion–solvent evaporation—DE) and top-down (high-pressure homogenization—HP) manufacturing approaches. The particle size, Z-potential, identity, stability, morphology, and solid-state properties were evaluated. RMNP biocompatibility was determined in human embryogenic kidney (HEK293) and human epidermal keratinocyte (HEKn) cell lines. RMNPs prepared by NC reached a particle size of 245.9 ± 31.5 nm and a Z-potential of −20.2 ± 1.56 mV; 253.1 ± 30.6 nm and −39.2 ± 0.56 mV compared to that obtained by DE, as well as RMNPs of 302.2 ± 69.9 nm and −38.6 ± 2.25 mV using HP. Spherical and solid nanostructures in the bottom-up approaches were observed; however, they were an irregular shape with a wide size distribution when the HP method was applied. Infrared (IR) spectra showed no changes in the chemical structure of the melanin after the manufacturing process but did exhibit an amorphous crystal rearrangement according to calorimetric and PXRD analysis. All RMNPs presented long stability in an aqueous suspension and resistance to being sterilized by wet steam and ultraviolet (UV) radiation. Finally, cytotoxicity assays showed that RMNPs are safe up to 100 μg/mL. These findings open new possibilities for obtaining melanin nanoparticles with potential applications in drug delivery, tissue engineering, diagnosis, and sun protection, among others.
- 19 December 2022
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 33 (1) , 230-236
The Antidiarrheal Activity of Octacosanol is Mediated by the Possible Participation of α2 Adrenoreceptors
- 19 December 2022
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 33 (1) , 230-236
The Antidiarrheal Activity of Octacosanol is Mediated by the Possible Participation of α2 Adrenoreceptors
- 4 June 2020
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 72 (9) , 1186-1198
Pharmacological characterization of the cardiovascular effect of Nibethione: ex vivo, in vivo and in silico studies
Objective This work describes the vasorelaxant and antihypertensive effects and the mechanism of action on vascular smooth muscle cells of Nibethione, a synthetic thiazolidinedione derivative. Additionally, evidence of its cytotoxicity is assessed. Methods Nibethione (NB) was synthesized, and its vasorelaxant effect and mechanism of action were assessed through ex vivo experiments. Molecular docking studies were used to predict the mode of interaction with L‐type Ca2+ channel, and in vivo antihypertensive activity was assayed on spontaneously hypertensive rats (SHR). The cytotoxicity potential was evaluated in porcine aortic endothelial cells (PAECs) from primary explants. Key findings Nibethione vasorelaxant effect was efficient on KCl (80 mm ) and NE‐contraction. This effect was deleteriously modified in the presence of potassium channel block drugs, while the maximal contraction induced with NE was significantly decreased by NB; the CaCl2‐induced contraction was abolished entirely. In vivo experiments showed that NB decreased diastolic blood pressure in 20.3 % after its administration on SHR. The molecular docking showed that NB blocks L‐type Ca2+ channel, and in vitro tests showed that NB did not produce cytotoxic activity on PAECs (IC50 >1000 µm ). Conclusions Nibethione showed in vivo antihypertensive and ex vivo vasorelaxant effects with implication of voltage‐dependent L‐type Ca2+ channel blocking, and this may contribute to the research of novel antihypertensive drugs.
- 4 June 2020
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 72 (9) , 1186-1198
Pharmacological characterization of the cardiovascular effect of Nibethione: ex vivo, in vivo and in silico studies
Objective This work describes the vasorelaxant and antihypertensive effects and the mechanism of action on vascular smooth muscle cells of Nibethione, a synthetic thiazolidinedione derivative. Additionally, evidence of its cytotoxicity is assessed. Methods Nibethione (NB) was synthesized, and its vasorelaxant effect and mechanism of action were assessed through ex vivo experiments. Molecular docking studies were used to predict the mode of interaction with L‐type Ca2+ channel, and in vivo antihypertensive activity was assayed on spontaneously hypertensive rats (SHR). The cytotoxicity potential was evaluated in porcine aortic endothelial cells (PAECs) from primary explants. Key findings Nibethione vasorelaxant effect was efficient on KCl (80 mm ) and NE‐contraction. This effect was deleteriously modified in the presence of potassium channel block drugs, while the maximal contraction induced with NE was significantly decreased by NB; the CaCl2‐induced contraction was abolished entirely. In vivo experiments showed that NB decreased diastolic blood pressure in 20.3 % after its administration on SHR. The molecular docking showed that NB blocks L‐type Ca2+ channel, and in vitro tests showed that NB did not produce cytotoxic activity on PAECs (IC50 >1000 µm ). Conclusions Nibethione showed in vivo antihypertensive and ex vivo vasorelaxant effects with implication of voltage‐dependent L‐type Ca2+ channel blocking, and this may contribute to the research of novel antihypertensive drugs.